CEO at NRFC
Stated the funding will help commercialize Quicktome and develop next generation clinical applications for brain-mapping technology.
How media typically covers David Gall
Referenced in coverage
Omniscient Neurotechnology secures $20 million Series D funding to scale its AI-powered brain-mapping platform (Quicktome) that personalizes neurosurgical treatment plans using MRI analysis.
“Stated the funding will help commercialize Quicktome and develop next generation clinical applications for brain-mapping technology.”